C-RVV

C:RVV - Revive Therapeutics Ltd. - http://www.revivethera.com

02:46:30 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
RVV - C	107.0	0.025	·	0.03	560.3	0.025			23.2	0	9	0.025 0.03 0.025	0.08 0.02	12:24:09	Apr 23	15 min RT 2¢
CSE - C	107.0	0.025	·	0.03	560.3	0.025			18.0	0	2	0.025 0.025 0.025	0.08 0.02	11:24:37		15 min
NEO ATS - U						0.03	+0.005	20.0	2.0		1	0.03 0.03 0.03		10:46:49		15 min
Chi-X - X						0.025			1.0		1	0.025 0.025 0.025		12:24:09		15 min
CX2 - H						0.03	+0.005	20.0	1.0		1	0.03 0.03 0.03		11:49:21		15 min
CXD - D						0.025			1.0		2			Apr 23		15 min
TriAct - M						0.025			0.2		2			Sep 08-20		15 min

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
NOTE: Delayed ATS trade data is included - click System Status for more information

Hide ATS · Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · Company · Participants · 1yr Bulletins · Sedar · Historical · Shorts · Portfolio

Recent Trades - All 9 today

More trades...

Time ET	Ex	Price	Change	Volume	Buyer	Seller	Markers
12:28:06	M	0.025		1	7 TD Sec	7 TD Sec	E
12:24:09	D	0.025		400	1 Anonymous	88 Credential	E
12:24:09	X	0.025		1,000	1 Anonymous	88 Credential	K
11:49:21	H	0.03	0.005	1,000	80 National Bank	1 Anonymous	K
11:49:21	M	0.03	0.005	200	80 National Bank	80 National Bank	E
11:24:37	C	0.025		16,000	80 National Bank	80 National Bank	K
10:46:49	U	0.03	0.005	2,000	2 RBC	2 RBC	K
09:30:00	D	0.025		600	80 National Bank	80 National Bank	E
09:30:00	C	0.025		2,000	85 Scotia	85 Scotia	K

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Price	Type	Headline
2024-04-23 10:17	C:RVV	0.025	News Release200	Revive receives Bucillamine FDA Type C meeting approval
2024-04-18 10:56	C:RVV	0.025	News Release200	Revive gets FDA acceptance for meeting request
2024-04-02 11:21	C:RVV	0.03	News Release200	Revive clinical study enrolls nearly 50% of sample
2024-03-27 13:25	C:RVV		News Release200	Revive submits meeting request to U.S. FDA
2024-03-19 10:11	C:RVV	0.03	News Release200	Revive receives notice to submit Type C meeting request
2024-03-12 09:42	C:RVV	0.035	News Release200	Revive recaps work on bucillamine, long COVID product
2024-02-28 18:51	C:RVV	0.025	SEDAR Interim Financial Statements812	SEDAR Interim Financial Statements
2024-02-28 18:51	C:RVV	0.025	SEDAR Interim MD & A813	SEDAR Interim MD & A
2024-02-26 16:24	C:RVV	0.025	News Release200	Revive Therapeutics closes $1.18M final tranche
2024-02-01 11:25	C:RVV	0.03	News Release200	Revive proposes phase 2/3 bucillamine clinical study
2024-01-31 17:24	C:RVV	0.025	News Release200	Revive closes $913,500 first tranche of placement
2024-01-24 18:00	C:RVV	0.04	News Release200	Revive arranges $3-million private placement
2024-01-16 11:28	C:RVV	0.035	News Release200	Revive talks Bucillamine for nerve agent exposure
2024-01-10 10:07	C:RVV	0.035	News Release200	Revive develops new bucillamine formulation
2023-12-20 13:11	C:RVV	0.03	News Release200	Revive shareholders approve all matters at AGSM
2023-12-18 10:14	C:RVV	0.03	News Release200	Revive, Attwill to develop Bucillamine formulation
2023-11-29 19:43	C:RVV	0.03	SEDAR Interim MD & A813	SEDAR Interim MD & A
2023-11-29 19:28	C:RVV	0.03	SEDAR Interim Financial Statements812	SEDAR Interim Financial Statements
2023-11-21 12:18	C:RVV	0.03	News Release200	Revive expects to complete bucillamine work by year-end
2023-11-06 10:30	C:RVV	0.03	News Release200	Revive unit, Lawson Health to develop long COVID tests

Date ET

Symbol

Price

Type

Headline

2024-04-23 10:17

C:RVV

0.025

News Release

Revive receives Bucillamine FDA Type C meeting approval

2024-04-18 10:56

C:RVV